NEW YORK, NY--(Marketwire - Dec 13, 2011) - Daxor Corporation (NYSE Amex: [ DXR ]), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Washington, DC VA Medical Center (VAMC).

The medical center staff of 1,700 provides care to over 50,000 veterans living in the District of Columbia and portions of Virginia and Maryland, and has over 500,000 outpatient visits each year. The VAMC is the only VA medical center to hold three medical school affiliations, and is one of the most visible and dynamic facilities in the VA system.

The medical center has a multi-million dollar research program that supports more than 100 investigators and 300 active research projects. Major research in alcoholism, diabetes, hypertension, cardiovascular disease and spinal cord regeneration is being conducted. The VAMC has sharing agreements with National Naval Medical Center in Bethesda and Walter Reed Army Medical Center, and was selected as a primary back-up facility during Operation Desert Shield/Desert Storm.

Dr. Bahman Sadr, MBBS, a Cambridge University Medical School graduate and currently an orthopaedic surgeon at VAMC, said "The orthopaedic unit of the Washington DC Veterans Administration has been interested in the measurement of blood volume changes after certain orthopaedic procedures. The advent of the BVA-100 system has made such measurements a reality and is a needed and exciting tool for future research in this area."

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at [ www.Daxor.com ].